Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04016246
Other study ID # 38RC18.123
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 7, 2019
Est. completion date October 7, 2024

Study information

Verified date April 2021
Source University Hospital, Grenoble
Contact Marie CHEVALLIER, MD
Phone +33476769248
Email MChevallier3@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators propose to evaluate premedication with Propofol compared to a control strategy including a placebo with a possible rescue treatment with ketamine to ensure pain control before LISA Procedure . Investigators hypothesize that sedation with Propofol is safe and non-inferior to placebo for the risk of Mechanical Ventilation in the 72 hours following the procedure.


Description:

Non-inferiority trial comparing Propofol versus placebo during the intra tracheal Less Invasive Surfactant Administration (LISA) in preterm babies < 32 weeks of gestation for the need for mechanical ventilation after the procedure. An open-label ketamine treatment as rescue is possible in each group. In each participating unit, information will be given to parents of preterm babies <32 wGA upon their admission to the delivery room or to the NICU (neonatal intensive care unit), and informed consent will be sought as soon as possible. Eligible babies presenting a RDS (respiratory distress syndrome) will be included and randomized to the control (placebo) group or Propofol group. While benefiting from Nasal Intermittent Positive Pressure Ventilation (NIPPV) the newborn will be prepared as usual for tracheal intubation. Trialists will be blinded to treatment allocation. The drug administration in the two groups will be titrated according to weight (0.5mg/kg per dose of Propofol or a similar volume of placebo). After each dose, a pain score (FANS) will be quickly evaluated within 2 minutes of the injection, to assess the need for a supplementary dose (up to a predefined limit) or rescue treatment by Ketamine. After the steps of sedation, the LISA procedure will be performed, with detailed data collection of per procedure events up to 72 hours of life. Babies will be subsequently managed as usual in each NICU and data will be collected about respiratory, neurological and hemodynamic outcomes during the hospital stay, and especially at discharge, 28 days, and 36 weeks. At two years of corrected age, a final examination will be performed to evaluate neurodevelopmental outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 542
Est. completion date October 7, 2024
Est. primary completion date October 7, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Preterm Infants < 32 wGA (weeks of gestational age) - Presenting a RDS (respiratory distress syndrome) - in the first 48 hours of life - treated by CPAP (continuous positive airway pressure) or BiPAP (Bilevel Positive Airway Pressure) - requiring surfactant : - FIO2 : (fraction of inspired oxygen) - if 28 - 31 SA : FiO2 =30% for a duration = 10mn - if <28 SA FIO2 =25% for a duration =10mn - SpO2 (arterial oxygen saturation) : to obtain a SpO2 between =88 and = 95% - Available IntraVenous line (peripheral, umbilical or central catheter) - Recipient of the French Social Security - Informed consent form signed Exclusion Criteria: - Congenital and/or major malformations - FIO2 >60% - Silverman score >6 - Contraindication to the use of Propofol : - Low Blood Pressure with 2 successive measurements (Mean < Gestational Age expressed in Weeks of Gestation) persisting after one volume expansion, - Use of inotropic medication to maintain a normal blood pressure. - Use of sedative or analgesic drugs (except paracetamol and ibuprofen) in the previous 24h - Coma, convulsions, areactivity at neurological examination

Study Design


Related Conditions & MeSH terms

  • Respiratory Distress Syndrome in Premature Infant
  • Respiratory Distress Syndrome, Adult
  • Respiratory Distress Syndrome, Newborn

Intervention

Drug:
Propofol-Lipuro
sedation of babies < 32wGA with propofol / placebo before a LISA Procedure
Placebos
injected to babies < 32wGA with propofol / placebo before a LISA Procedure

Locations

Country Name City State
France Chu Amiens Amiens
France Chu Angers Angers
France Chu Brest Brest
France Chu Chambery Chambéry
France Chi Creteil Créteil
France CHU Grenoble Alpes Grenoble Isère
France Chu Limoges Limoges
France Ap-H Marseille Marseille
France Chu Nantes Nantes
France Chu Nimes Nîmes
France Chi Poissy St Germain Poissy
France Ch Rennes Rennes
France centre hospitalier deTroyes Troyes Aube

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

References & Publications (12)

Berde CB, Walco GA, Krane EJ, Anand KJ, Aranda JV, Craig KD, Dampier CD, Finkel JC, Grabois M, Johnston C, Lantos J, Lebel A, Maxwell LG, McGrath P, Oberlander TF, Schanberg LE, Stevens B, Taddio A, von Baeyer CL, Yaster M, Zempsky WT. Pediatric analgesic — View Citation

Bourgoin L, Caeymaex L, Decobert F, Jung C, Danan C, Durrmeyer X. Administering atropine and ketamine before less invasive surfactant administration resulted in low pain scores in a prospective study of premature neonates. Acta Paediatr. 2018 Jul;107(7):1 — View Citation

Dargaville PA, Kamlin CO, De Paoli AG, Carlin JB, Orsini F, Soll RF, Davis PG. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation. BMC Pediatr. 2014 Aug 27;14:213. doi: 10.1186/1471-2431-14-2 — View Citation

Dekker J, Lopriore E, Rijken M, Rijntjes-Jacobs E, Smits-Wintjens V, Te Pas A. Sedation during Minimal Invasive Surfactant Therapy in Preterm Infants. Neonatology. 2016;109(4):308-13. doi: 10.1159/000443823. Epub 2016 Feb 24. — View Citation

Dekker J, Lopriore E, van Zanten HA, Tan RNGB, Hooper SB, Te Pas AB. Sedation during minimal invasive surfactant therapy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019 Jul;104(4):F378-F383. doi: 10.1136/archdischild-2018-315015. Ep — View Citation

Descamps CS, Chevallier M, Ego A, Pin I, Epiard C, Debillon T. Propofol for sedation during less invasive surfactant administration in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2017 Sep;102(5):F465. doi: 10.1136/archdischild-2017-312791. Epub 201 — View Citation

Durrmeyer X, Daoud P, Decobert F, Boileau P, Renolleau S, Zana-Taieb E, Saizou C, Lapillonne A, Granier M, Durand P, Lenclen R, Coursol A, Nicloux M, de Saint Blanquat L, Shankland R, Boëlle PY, Carbajal R. Premedication for neonatal endotracheal intubati — View Citation

Ghanta S, Abdel-Latif ME, Lui K, Ravindranathan H, Awad J, Oei J. Propofol compared with the morphine, atropine, and suxamethonium regimen as induction agents for neonatal endotracheal intubation: a randomized, controlled trial. Pediatrics. 2007 Jun;119(6 — View Citation

Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M, Groneck P, Weller U, Möller J, Härtel C, Haller S, Roth B, Herting E; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatm — View Citation

Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013 Feb;131(2):e502-9. doi: 10.1542/peds.2012-0603. Epub 2013 Jan 28. — View Citation

Klotz D, Porcaro U, Fleck T, Fuchs H. European perspective on less invasive surfactant administration-a survey. Eur J Pediatr. 2017 Feb;176(2):147-154. doi: 10.1007/s00431-016-2812-9. Epub 2016 Dec 9. — View Citation

Owen LS, Manley BJ. Nasal intermittent positive pressure ventilation in preterm infants: Equipment, evidence, and synchronization. Semin Fetal Neonatal Med. 2016 Jun;21(3):146-53. doi: 10.1016/j.siny.2016.01.003. Epub 2016 Feb 26. Review. — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary need for mechanical ventilation after the procedure Rate of mechanical ventilation from the start of the LISA procedure up to 72 hours of life. 72hours
Secondary Rate of MV (mechanical ventilation ) in each class of GA (<28, 28-31wGA) Rate of MV (mechanical ventilation
) from the start of the LISA procedure up to 72 hours of life in each class of GA (<28, 28-31wGA)
72hours
Secondary FANS during LISA and 1h after LISA Faceless acute neonatal pain scale (FANS) assessed during LISA and 1 hour after the procedure by an independent operator. 1hour
Secondary number of ketamine administrations for rescue Number of ketamine administrations for rescue in order to obtain a FANS score <6 and to be able to proceed to LISA. before LISA Procedure
Secondary Number of laryngoscopies Number of laryngoscopies needed to perform LISA during LISA Procedure (T0)
Secondary Tolerance and efficacy (Per procedure events): Apnea Apnea requiring bag mask ventilation during LISA Procedure (T0)
Secondary Tolerance and efficacy (Per procedure events): emergency intubation Emergency intubation after the drug injection before the LISA procedure can be performed or within 1h following the drug injection from drug injection to 1hour after
Secondary Tolerance and efficacy (Per procedure events): Viby Mogensen score Clinician's satisfaction during laryngoscopy with the Viby Mogensen score :
Item Score 1 Score 2 Score 3 Score 4 Laryngoscopy Easy Fair Difficult Impossible Vocal cords Open Moving Closing Closed Coughing None Slight Moderate Severe Jaw relaxation Complete Slight Stiff Rigid Limb movements None Slight Moderate Severe
the total score is calculated adding each item scores. min score = 5. max score = 20. An easy intubation would obtain a low score and a difficult intubation would have a high score.
during LISA Procedure
Secondary BPD (bronchopulmonary dysplasia) at 36 weeks of Gestational Age Broncho Pulmonary Dysplasia at 36 weeks of Gestational Age equivalent to 36 weeks of Gestational Age
Secondary In-hospital morbidity and mortality: pneumothorax Pneumothorax within 72hours 72hours post LISA Procedure
Secondary In-hospital morbidity and mortality: Necrotizing Enterocolitis necrotizing enterocolitis during hospitalization the day of discharge from hospital (the day depends to each participant : between 36-45 weeks of Gestational Age)
Secondary In-hospital morbidity and mortality : sepsis proven sepsis during hospitalization the day of discharge from hospital (the day depends to each participant : between 36-45 weeks of Gestational Age)
Secondary In-hospital morbidity and mortality: retinopathy retinopathy of prematurity during hospitalization the day of discharge from hospital (the day depends to each participant : between 36-45weeks of gestational ageGA)
Secondary In-hospital morbidity and mortality periventricular leukomalacia or grade 3 or 4 intraventricular hemorrhage during hospitalization the day of discharge from hospital (the day depends to each participant : between 36-45weeks of Gestational Age)
Secondary In-hospital morbidity and mortality: patent ductus arteriosus treatment of a patent ductus arteriosus during hospitalization the day of discharge from hospital (the day depends to each participant : between 36-45 weeks of Gestational Age)
Secondary In-hospital morbidity and mortality: death 36weeks of Gestational Age Death at 36 weeks of Gestational Age equivalent to 36 weeks of Gestational Age
Secondary In-hospital morbidity and mortality: death during hospitalization in-hospital mortality the day of discharge from hospital (the day depends to each participant : between 36-45weeks of Gestational Age)
Secondary At two years of corrected age: ASQ (Ages and Stages Questionnaire) ASQ (Ages and Stages Questionnaire) questionnaire is a general developmental screening tool (5 areas are evaluated: Communication, gross motor, fine motor, problem solving, and personal-social). Total score is the sum of each of the 5 area scores (wich are between 0-60. Total score is between 0 and 300. The higher the score is, the best developed the children is. 2 years (corrected age)
Secondary At two years of corrected age: motor function Gross Motor Function Classification Scale (GMFCS) looks at movements such as sitting, walking and use of mobility devices. It is helpful because it provides families and clinicians with a clear description of a child's current motor function, and an idea of what equipment or mobility aids a child may need in the future, e.g. crutches, walking frames or wheelchairs.
Participant will be assignated to one of the 5 levels by the clinicians : a patient who is in level 5 has more motor impairments than a patient in level 1.
2 years (corrected age)
Secondary At two years of corrected age: vision Visual functions : a clinical examination will conclude if the participant has a visual deficit or not. And in the deficit case, what kind of vision pathology. 2 years (corrected age)
Secondary At two years of corrected age: audition Hearing functions : a clinical examination will conclude if the participant has a hearing deficit or not. And in the deficit case, what kind of audition pathology. 2 years (corrected age)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04118400 - Ventilator Weaning Outcome Between NIV-NAVA and Nasal CPAP (or IMV ) Modes in Premature Neonates
Completed NCT01941745 - Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT04019106 - Budesonide With Intratracheal Surfactants in Extremely Preterm Infants Phase 1/Phase 2
Not yet recruiting NCT04862377 - Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. Phase 3
Not yet recruiting NCT05791331 - REspiratory MEchanics for Delivering Individualised Exogenous Surfactant N/A
Completed NCT04086095 - Feasibility Study - Neofact N/A
Not yet recruiting NCT05609877 - The NONA-LISA Trial N/A
Recruiting NCT04326270 - Crossover Comparison of Tidal Volume Delivery During Nasal Intermittent Positive Pressure Ventilation in Preterm Infants: Infant Cannula vs. Nasal Continuous Positive Airway Pressure Prongs N/A
Active, not recruiting NCT03969992 - A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact Phase 2
Completed NCT03700606 - Physiological Changes With High-Flow Nasal Cannula N/A
Recruiting NCT04359134 - Combined Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress.
Not yet recruiting NCT06229821 - Safety and Efficacy of Intrapulmonary Percussive Ventilation in Preterm Infants N/A
Recruiting NCT05446389 - PAL to Improve Oral Feeding for Infants With Chronic Lung Disease N/A
Withdrawn NCT04914715 - nHFOV Versus Invasive Conventional Ventilation for Preterm Neonates With Respiratory Distress Syndrome N/A
Recruiting NCT03825835 - 30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants N/A
Recruiting NCT03562182 - Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA
Completed NCT05031650 - Open Lung Strategy During Non-Invasive Respiratory Support of Very Preterm Infants in the Delivery Room N/A
Completed NCT03306524 - The Role of Circuit Flow During Mechanical Ventilation of Neonates N/A
Completed NCT01473264 - Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS) Phase 1/Phase 2
Completed NCT03548324 - Enteral Nutrition Tolerance And REspiratory Support (ENTARES) N/A